The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

This study is currently recruiting participants.

Verified by Staten Island University Hospital, April 2008

Sponsored by:	Staten Island University Hospital
Information provided by:	Staten Island University Hospital
ClinicalTrials.gov Identifier:	NCT00665613

Purpose

The purpose of this study is to determine if osteoporosis is an unrecognized complication of chronic anticoagulation with warfarin.

Condition
Osteoporosis

MedlinePlus related topics: Blood Thinners Osteoporosis

Drug Information available for: Warfarin Warfarin potassium Warfarin sodium

Study Type:	Observational
Study Design:	Case-Only, Retrospective
Official Title:	The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

Further study details as provided by Staten Island University Hospital:

Estimated Enrollment:	3000
Study Start Date:	October 2004

Eligibility

Study Population

patients on warfarintherapy in the SIUH coumadin center

Criteria

Inclusion Criteria:

Exclusion Criteria:

Patients on bisphosphates, SERMS, anticonvulsants, estrogens, androgens, calcitonin, hctz and thyroid hormone replacement

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00665613

Contacts

Contact: Mario Castellanos, MD

7182269000

Locations

United States, New York
Staten Island University Hospital	Recruiting
Staten Island, New York, United States, 10305
Contact: Mario Castellanos, MD 718-226-9000 mcastellanos@siuh.edu
Principal Investigator: Mario Castellanos, MD

Sponsors and Collaborators

Staten Island University Hospital

More Information

Responsible Party:	staten island hospital irb ( Mario Castellanos, MD )
Study ID Numbers:	04-054
Study First Received:	April 22, 2008
Last Updated:	April 23, 2008
ClinicalTrials.gov Identifier:	NCT00665613
Health Authority:	United States: Institutional Review Board

Keywords provided by Staten Island University Hospital:

warfarin use

Study placed in the following topic categories:

Musculoskeletal Diseases
Osteoporosis
Bone Diseases, Metabolic
Warfarin
Bone Diseases

Additional relevant MeSH terms:

Anticoagulants
Therapeutic Uses
Hematologic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009